Literature DB >> 1329622

Activity of azithromycin against Mycobacterium avium infection in beige mice.

M H Cynamon1, S P Klemens.   

Abstract

The comparative activities of azithromycin and clarithromycin and the activities of azithromycin alone and in combination with other antimycobacterial agents were evaluated in the beige mouse model of disseminated Mycobacterium avium complex infection. Azithromycin was similar in activity to clarithromycin. Azithromycin plus clofazimine plus ethambutol reduced the number of splenic organisms more than azithromycin alone, while the combination was less active than azithromycin alone for bacteria in lungs. Rifabutin had activity similar to that of azithromycin for organisms in spleens and lungs. Rifabutin plus azithromycin was more active than either agent alone for organisms in spleens, but the combination's activity was not significantly different from that of rifabutin for organisms in lungs. The activity of azithromycin against several M. avium complex isolates was evaluated. The reduction of viable cell counts in spleens ranged from 1.7 to 0.8 log units. For the three isolates studied, there was little correlation between the in vitro MIC and the in vivo activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329622      PMCID: PMC192015          DOI: 10.1128/AAC.36.8.1611

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.

Authors:  S Naik; R Ruck
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex.

Authors:  C B Inderlied; P T Kolonoski; M Wu; L S Young
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

3.  In vivo activities of newer rifamycin analogs against Mycobacterium avium infection.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

4.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

5.  Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice.

Authors:  S P Klemens; M H Cynamon; C E Swenson; R S Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS.

Authors:  L S Young; L Wiviott; M Wu; P Kolonoski; R Bolan; C B Inderlied
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

7.  In vitro and in vivo activities of clarithromycin against Mycobacterium avium.

Authors:  P B Fernandes; D J Hardy; D McDaniel; C W Hanson; R N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

8.  Liposome-encapsulated-amikacin therapy of Mycobacterium avium complex infection in beige mice.

Authors:  M H Cynamon; C E Swenson; G S Palmer; R S Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

9.  Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.

Authors:  A E Girard; D Girard; A R English; T D Gootz; C R Cimochowski; J A Faiella; S L Haskell; J A Retsema
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

10.  Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial.

Authors:  B Dautzenberg; C Truffot; S Legris; M C Meyohas; H C Berlie; A Mercat; S Chevret; J Grosset
Journal:  Am Rev Respir Dis       Date:  1991-09
View more
  14 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

2.  Evidence for a reduced chemokine response in the lungs of beige mice infected with Mycobacterium avium.

Authors:  M Florido; R Appelberg; I M Orme; A M Cooper
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

Review 3.  Beige mouse model for Mycobacterium avium complex disease.

Authors:  P R Gangadharam
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

4.  Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy.

Authors:  L E Bermudez; M Petrofsky; P Kolonoski; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

5.  Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex.

Authors:  S P Klemens; M A Grossi; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

6.  Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages.

Authors:  C O Onyeji; C H Nightingale; D P Nicolau; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 7.  Mycobacterium avium complex: advances in therapy.

Authors:  D V Havlir
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

Review 8.  Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome.

Authors:  L B Barradell; G L Plosker; D McTavish
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

9.  Comparative activities of azithromycin and clarithromycin against Mycobacterium avium infection in beige mice.

Authors:  M H Cynamon; S P Klemens; M A Grossi
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.